GenScript

Piscataway, NJ / Nanjing, China
CAR-T Cell Therapy Gene Editing
Program data pending ClinicalTrials.gov matching · Last scored 2026-03-04
64.0
Signal Score
○ FDA Inspections ○ Clinical Trials ○ SEC Filings ✓ Press (8)

Quick Facts: GenScript

Signal Score
64.0/100 (as of 2026-03-04)
Quality Compliance
Assessment pending
Headquarters
Piscataway, NJ / Nanjing, China
Modalities
CAR-T, Cell Therapy, Gene Editing
Active Programs
No ClinicalTrials.gov matches confirmed
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

Signal Score & Pillar Breakdown

Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs — no verified data
Sponsors— no verified data
ModalitiesCAR-T, Cell Therapy, Gene Editing
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability 65.0
Publicly traded — financial transparency
BIOSECURE Act exposure risk
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Publicly traded — financial transparency
BIOSECURE Act exposure risk
Capacity 63.0
2 manufacturing sites
Regulatory milestones (2 articles)
Sites: Piscataway, NJ, Nanjing, China
Source: SEC EDGAR, press monitoring, company profiles
2 manufacturing sites
Recent Press8 articles
2 manufacturing sites
Regulatory milestones (2 articles)

Recent News 8 articles

general 2026-03-17
GenScript reports strong fiscal 2025 results from platform strategy - Vietnam Investment Review - VIR
GenScript reports strong fiscal 2025 results from platform strategy  Vietnam Investment Review - VIR
Source →
regulatory 2026-03-16
GenScript launches first European mRNA production hub in Delft, bolstering EU biotech leadership - Indian Pharma Post
GenScript launches first European mRNA production hub in Delft, bolstering EU biotech leadership  Indian Pharma Post
Source →
general 2026-03-16
GenScript Biotech Corp Reports Strong FY2025 Results as Integrated Platform Strategy and Global Execution Drive High-Quality Growth - Bolsamania
GenScript Biotech Corp Reports Strong FY2025 Results as Integrated Platform Strategy and Global Execution Drive High-Quality Growth  Bolsamania
Source →
regulatory 2026-03-16
GenScript launches first European mRNA production hub in Delft, bolstering EU biotech leadership - Indian Pharma Post
GenScript launches first European mRNA production hub in Delft, bolstering EU biotech leadership  Indian Pharma Post
Source →
general 2026-03-13
GenScript opens its first European mRNA production site - Scientist Live
GenScript opens its first European mRNA production site  Scientist Live
Source →
general 2026-03-12
GenScript Strengthens Transatlantic Biotech Infrastructure with European mRNA Hub - BioSpace
GenScript Strengthens Transatlantic Biotech Infrastructure with European mRNA Hub  BioSpace
Source →
general 2026-03-12
GenScript Strengthens Transatlantic Biotech Infrastructure with European mRNA Hub - The AI Journal
GenScript Strengthens Transatlantic Biotech Infrastructure with European mRNA Hub  The AI Journal
Source →
general 2026-03-12
GenScript Strengthens Transatlantic Biotech Infrastructure with European mRNA Hub - BeBeez International
GenScript Strengthens Transatlantic Biotech Infrastructure with European mRNA Hub  BeBeez International
Source →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
CAR-T CDMOs → Cell Therapy CDMOs → Gene Editing CDMOs →